Search > Results
You searched for: EV210109 (EV-TRACK ID)
Showing 1 - 3 of 3
Showing 1 - 3 of 3
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV210109 | 2/3 | Homo sapiens | Blood plasma | Asymmetric flow field-flow fractionation | Cai, Tanxi | 2021 | 75% | |
Study summaryFull title
All authors
Tanxi Cai, Qing Zhang, Bowen Wu, Jifeng Wang, Na Li, Tingting Zhang, Zhipeng Wang, Jianjun Luo, Xiaojing Guo, Xiang Ding, Zhensheng Xie, Lili Niu, Weihai Ning, Zhen Fan, Xiaowei Chen, Xiangqian Guo, Runsheng Chen, Hongwei Zhang, Fuquan Yang
Journal
J Extracell Vesicles
Abstract
Advancements in omics-based technologies over the past few years have led to the discovery of numero (show more...)
EV-METRIC
75% (96th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
Asymmetric flow field-flow fractionation
Protein markers
EV: TSG101/ CD81/ HSP90/ CD63/ CD9
non-EV: APOB/ APOA1 Proteomics
yes
Show all info
Study aim
Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
Other
Name other separation method
Asymmetric flow field-flow fractionation
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Detected EV-associated proteins
CD9/ CD63/ HSP90/ TSG101/ CD81
Not detected contaminants
APOA1/ APOB
Proteomics database
Yes:
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
144.2+/-2.8
EV concentration
Yes
Particle yield
Yes, as number of particles per milliliter of starting sample 2.00E+10
EM
EM-type
Transmission-EM
Image type
Wide-field
|
||||||||
EV210109 | 3/3 | Homo sapiens | Blood plasma | Asymmetric flow field-flow fractionation | Cai, Tanxi | 2021 | 75% | |
Study summaryFull title
All authors
Tanxi Cai, Qing Zhang, Bowen Wu, Jifeng Wang, Na Li, Tingting Zhang, Zhipeng Wang, Jianjun Luo, Xiaojing Guo, Xiang Ding, Zhensheng Xie, Lili Niu, Weihai Ning, Zhen Fan, Xiaowei Chen, Xiangqian Guo, Runsheng Chen, Hongwei Zhang, Fuquan Yang
Journal
J Extracell Vesicles
Abstract
Advancements in omics-based technologies over the past few years have led to the discovery of numero (show more...)
EV-METRIC
75% (96th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Giloma cancer patients
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
Asymmetric flow field-flow fractionation
Protein markers
EV: None
non-EV: None Proteomics
yes
Show all info
Study aim
Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
Other
Name other separation method
Asymmetric flow field-flow fractionation
Characterization: Protein analysis
Protein Concentration Method
BCA
Proteomics database
Yes:
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210109 | 1/3 | Homo sapiens | Glioma cells | (d)(U)C | Cai, Tanxi | 2021 | 67% | |
Study summaryFull title
All authors
Tanxi Cai, Qing Zhang, Bowen Wu, Jifeng Wang, Na Li, Tingting Zhang, Zhipeng Wang, Jianjun Luo, Xiaojing Guo, Xiang Ding, Zhensheng Xie, Lili Niu, Weihai Ning, Zhen Fan, Xiaowei Chen, Xiangqian Guo, Runsheng Chen, Hongwei Zhang, Fuquan Yang
Journal
J Extracell Vesicles
Abstract
Advancements in omics-based technologies over the past few years have led to the discovery of numero (show more...)
EV-METRIC
67% (94th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: Alix/ CD81/ CD63/ CD9/ Annexin A1
non-EV: Calnexin Proteomics
yes
Show all info
Study aim
Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
Glioma cells
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
overnight (16h) at >=100,000g
Cell viability (%)
95
Cell count
4.00E+08
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
70
Pelleting: rotor type
Type 45 Ti
Pelleting: speed (g)
100000
Wash: volume per pellet (ml)
70
Wash: time (min)
70
Wash: Rotor Type
Type 45 Ti
Wash: speed (g)
100000
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Detected EV-associated proteins
CD9/ CD63/ Annexin A1/ Alix/ CD81
Not detected contaminants
Calnexin
Proteomics database
Yes:
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
124.9+/-7.9
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 4.00E+08
EM
EM-type
Transmission-EM
Image type
Wide-field
|
||||||||
1 - 3 of 3 |
EV-TRACK ID | EV210109 | ||
---|---|---|---|
species | Homo sapiens | ||
sample type | Blood plasma | Blood plasma | Cell culture |
cell type | NA | NA | Glioma cells |
medium | NA | NA | EV-depleted medium |
condition | Control condition | Giloma cancer patients | Control condition |
separation protocol | Asymmetric flow field-flow fractionation | Asymmetric flow field-flow fractionation | (d)(U)C |
Exp. nr. | 2 | 3 | 1 |
EV-METRIC % | 75 | 75 | 67 |